EPISODE · Apr 29, 2026 · 2 MIN
AbbVie Q1: New Drugs Shine, Humira Dips
from The Daily News Now! Business
AbbVies Q1 results exceed expectations, with adjusted earnings per share up 7.7% to $2.65 and net revenues climbing 12.4% to $15 billion. Newer immunology drugs Skyrizi and Rinvoq drive growth, while Humira sales decline due to biosimilars. Neuroscience and aesthetics segments also perform well, with Botox Therapeutic and Botox Cosmetic reaching new milestones. CEO Robert Michael praises the strong start, and investors react positively, pushing shares up in premarket trading. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5dd66b569022e7d9
NOW PLAYING
AbbVie Q1: New Drugs Shine, Humira Dips
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m